Ethereum Price Prediction: Will Ethereum Coin Hold the $2,400 Support?
Ethereum Price Prediction: Key Support and Resistance Levels at Play
The Ethereum coin is currently trading around $2,427.5, stuck in a tight range between key support at $2,400 and the 200 EMA resistance at $2,466.1. The 4-hour chart reveals a clear battle zone, with multiple tests of the $2,400 area highlighted by green arrows—signaling strong historical buying pressure.
ETH/USD 4-hours chart - TradingView
However, the price is failing to reclaim the $2,535 resistance zone, suggesting that upside momentum is limited unless bulls step in with force .
Technical Indicators: RSI and Moving Averages
- RSI (Relative Strength Index) is neutral at 50.84, indicating no strong bullish or bearish momentum.
- 200 EMA (Exponential Moving Average) is currently acting as dynamic resistance.
- Price is consolidating below the 200 EMA, which often implies bearish bias unless a clear breakout occurs.
Critical Levels to Watch
Support:
- $2,400 – Holding for now, marked by multiple bounces (green arrows). A break below this level could trigger a drop to the next key level.
- $2,200 – The next significant support if $2,400 fails.
Resistance:
- $2,466 (200 EMA ) – Immediate resistance.
- $2,535 – A strong horizontal resistance level.
- $2,732 – Medium-term bullish target if the price breaks above $2,535.
Trade Setup: What Traders Should Look For ETH Coin
Bullish Scenario:
If ETH breaks above the 200 EMA and holds above $2,466, a move toward $2,535 becomes likely. A daily close above $2,535 would open the door to $2,732.
✅ Long Entry: Above $2,470
🎯 Target: $2,535 → $2,732
🛑 Stop Loss: Below $2,400
Bearish Scenario:
If Ethereum fails to hold $2,400, a decline toward $2,200 is likely.
🔻 Short Entry: Below $2,390
🎯 Target: $2,200
🛑 Stop Loss: Above $2,470
Neutral Zone:
ETH is currently ranging between $2,400 – $2,466. Traders should wait for a decisive breakout before entering large positions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. Stock IPO Preview | From Losses to Net Profit of 5.46 Million: The "Three-Dimensional" Platform Business Strategy with a Taste for Golf
Crossing the break-even line, the growth inflection point has arrived.
Core CPI Exceeds Expectations Again, Fed Hawks Loud! 2027 FOMC Voting Member Directly Calls Inflation Hot
Austan Goolsbee, President of the Chicago Federal Reserve, stated that officials must address the issue of high inflation, and described the October consumer price report as worrisome.
Weight-loss drug receives FDA warning for rare eye disease; Novo Nordisk (NVO.US) and Eli Lilly (LLY.US): No evidence of causality
The FDA requires all GLP-1 drugs to include a warning about the rare eye disease NAION. Novo Nordisk and Eli Lilly deny any causality, while Citi states that the impact on adoption is limited.

